Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee

R D Rubens; S B Kaye; M Soukop; C J Williams; M H Brampton; A L Harris

doi:10.1038/bjc.1991.488

Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee

Br J Cancer. 1991 Dec;64(6):1187-8. doi: 10.1038/bjc.1991.488.

Authors

R D Rubens¹, S B Kaye, M Soukop, C J Williams, M H Brampton, A L Harris

Affiliation

¹ ICRF Department of Clinical Oncology, UMDS, Guy's Hospital, London.

Abstract

Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for the more effective use of this agent are discussed.

Publication types

Clinical Trial

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use*
Breast Neoplasms / drug therapy*
Drug Evaluation
Humans
Hydroxamic Acids / therapeutic use*
Ribonucleotide Reductases / antagonists & inhibitors

Substances

Antimetabolites, Antineoplastic
Hydroxamic Acids
Ribonucleotide Reductases
3,4-dihydroxybenzohydroxamic acid